No Data
No Data
Centessa Pharmaceuticals | 10-Q: Quarterly report
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 1Q Loss/Shr 38c >CNTA
Press Release: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of Serp
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Wednesday's premarket activity, as earnings continue t
Express News | Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals (CNTA) said Tuesday it is seeking to raise $100 million from an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proposed
Jaguar8 : A big ouch
TrytosaveabitOP Jaguar8: Not as bad as I thought!
Jaguar8 TrytosaveabitOP: CYN was bad haha
TrytosaveabitOP Jaguar8: Yes it was! Hehehe
Jaguar8 TrytosaveabitOP: I’m sure a lot got caught off guard and end up bagholding. Scaling out is key
View more comments...